With multiple drugs for Alzheimer's Disease (AD) in the pipeline or in Clinical Trials, billions of dollars is at stake. Despite the size of investment, there are more failures than even a tiny successes.
What do you think is wrong with the strategy?
Monolithic view point is what I think is responsible for the massive failure of R&D. There is always one target which is exploited at one time, however given the complexity and absence of early diagnosis, a multi pronged approach should help. Many researchers are trying different approaches but sadly, when it comes to drug development, either Amyloid or Tau approaches win.
There are also very little efforts for the most crucial step: The Early Diagnosis. Most of the therapies and treatments are targeted when it's already too late.
Can digital biomarkers help??
We don't know but still with evolving technologies, this could be a viable option.